Therapeutic efficacy of oral immunization with attenuated Salmonella typhimurium expressing Helicobacter pylori CagA, VacA and UreB fusion proteins in mice model

Vaccine

Volumn 29, Issue 38, 2011, Pages 6679-6685

  Liu, Kai Yun ^a   Shi, Yun ^a   Luo, Ping ^a   Yu, Shu ^a   Chen, Li ^a   Zhao, Zhuo ^a   Mao, Xu Hu ^a   Guo, Gang ^a   Wu, Chao ^a   Zou, Quan Ming ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Attenuated Salmonella; Helicobacter pylori; Therapeutic immunization; Vaccine

Indexed keywords

BACTERIAL VECTOR; CAGA PROTEIN; CAGA VACA UREB FUSION PROTEIN; HELICOBACTER PYLORI VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; SALMONELLA VECTOR; UNCLASSIFIED DRUG; UREASE; VACUOLATING TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IMMUNIZATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; TH1 CELL; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL LOAD; BACTERIAL PROTEINS; BACTERIAL VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNITY, MUCOSAL; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; RODENT DISEASES; SALMONELLA TYPHIMURIUM; STOMACH; UREASE; VACCINES, SYNTHETIC;

EID: 80051665641     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.099     Document Type: Article

References (43)

1. Hirai Y., Hayashi S., Shimomura H., Oguma K., Yokota K. Association of Helicobacter pylori with gastroduodenal diseases. Jpn J Infect Dis 2000, 52(5):183-197.
2. Wong B.C., Lam S.K., Lai K.C., Hu W.H., Ching C.K., Ho J., et al. Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. Aliment Pharmacol Ther 1999, 13(3):303-309.
3. Wheeldon T.U., Hoang T.T., Phung D.C., Bjorkman A., Granstrom M., Sorberg M. Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. Aliment Pharmacol Ther 2005, 21(8):1047-1053.
4. Boyanova L., Mentis A., Gubina M., Rozynek E., Gosciniak G., Kalenic S., et al. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect 2002, 8(7):388-396.
5. Maeda K., Yamashiro T., Minoura T., Fujioka T., Nasu M., Nishizono A. Evaluation of therapeutic efficacy of adjuvant Helicobacter pylori whole cell sonicate in mice with chronic H. pylori infection. Microbiol Immunol 2002, 46(9):613-620.
6. Nystrom J., Raghavan S., Svennerholm A.M. Mucosal immune responses are related to reduction of bacterial colonization in the stomach after therapeutic Helicobacter pylori immunization in mice. Microbes Infect 2006, 8(2):442-449.
7. Nystrom J., Svennerholm A.M. Oral immunization with HpaA affords therapeutic protective immunity against H. pylori that is reflected by specific mucosal immune responses. Vaccine 2007, 25(14):2591-2598.
8. Rossi G., Ruggiero P., Peppoloni S., Pancotto L., Fortuna D., Lauretti L., et al. Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy. Infect Immun 2004, 72(6):3252-3259.
9. Zhou W.Y., Shi Y., Wu C., Zhang W.J., Mao X.H., Guo G., et al. Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model. Vaccine 2009, 27(36):5013-5019.
10. Ermak T.H., Giannasca P.J., Nichols R., Myers G.A., Nedrud J., Weltzin R., et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med 1998, 188(12):2277-2288.
11. Shi T., Liu W.Z., Gao F., Shi G.Y., Xiao S.D. Intranasal CpG-oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferongamma correlate with the protection. Helicobacter 2005, 10(1):71-79.
12. Sawai N., Kita M., Kodama T., Tanahashi T., Yamaoka Y., Tagawa Y., et al. Role of gamma interferon in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Infect Immun 1999, 67(1):279-285.
13. Lee J.S., Jung I.D., Lee C.M., Park J.W., Chun S.H., Jeong S.K., et al. Outer membrane protein A of Salmonella enterica serovar Typhimurium activates dendritic cells and enhances Th1 polarization. BMC Microbiol 2010, 10(1):263.
14. Hase K., Kawano K., Nochi T., Pontes G.S., Fukuda S., Ebisawa M., et al. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 2009, 462(7270):226-230.
15. Sirard J.C., Niedergang F., Kraehenbuhl J.P. Live attenuated Salmonella: a paradigm of mucosal vaccines. Immunol Rev 1999, 171:5-26.
16. Chatfield S.N, Strugnell R.A., Dougan G. Live Salmonella as vaccines and carriers of foreign antigenic determinants. Vaccine 1989, 7(6):495-498.
17. Suerbaum S., Josenhans C. Virulence factors of Helicobacter pylori: implications for vaccine development. Mol Med Today 1999, 5(1):32-39.
18. Zavala-Spinetti L., Breslin M.B., Correa H., Begue R.E. Development and evaluation of a DNA vaccine based on Helicobacter pylori urease B: failure to prevent experimental infection in the mouse model. Helicobacter 2006, 11(6):517-522.
19. Corthesy B., Boris S., Isler P., Grangette C., Mercenier A. Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori urease B subunit partially protects against challenge with Helicobacter felis. J Infect Dis 2005, 192(8):1441-1449.
20. Lin H.J., Yang Q., Li J., Liu Y., Wang Q.Y. Immunization with catalase and UreB two-valence vaccine for preventing Helicobacter pylori infection in mice. Nan Fang Yi Ke Da Xue Xue Bao 2008, 28(3):436-437.
21. Cover T.L., Blaser J. Purification and characterization of the vacuolating toxin from Helicobacter pylori. J Biol Chem 1992, 267(15):10570-10575.
22. Covacci A., Censini S., Bugnoli M., Petracca R., Burroni D., Macchia G., et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA 1993, 90(12):5791-5795.
23. Tsuda M., Karita M., Morshed M.G., Okita K., Nakazawa T. A urease-negative mutant of Helicobacter pylori constructed by allelic exchange mutagenesis lacks the ability to colonize the nude mouse stomach. Infect Immun 1994, 62(8):3586-3589.
24. Wang P., Sidney J., Dow C., Mothe B., Sette A., Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 2008, 4(4):e1000048.
25. Nielsen M., Lundegaard C., Lund O. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 2007, 8:238.
26. Lengler J., Holzmuller H., Salmons B., Gunzburg W.H., Renner M. FMDV-2A sequence and protein arrangement contribute to functionality of CYP2B1-reporter fusion protein. Anal Biochem 2005, 343(1):116-124.
27. Koepf E.K., Petrassi H.M., Ratnaswamy G., Huff M.E., Sudol M., Kelly J.W. Characterization of the structure and function of W→F WW domain variants: identification of a natively unfolded protein that folds upon ligand binding. Biochemistry 1999, 38(43):14338-14351.
28. George R.A., Heringa J. An analysis of protein domain linkers: their classification and role in protein folding. Protein Eng 2002, 15(11):871-879.
29. Jeong D.W., Lee J.H., Lee H.J. Construction of recombinant Lactobacillus casei strains using splicing by overlap extension. J Microbiol Biotechnol 2008, 18(12):1953-1957.
30. Wu Y.N., Zou Q.M., Luo P., Guo G., Wang X.Q. Preparation of anti-Helicobacter pylori UreB monoclonal antibody and the detection of the ability of inhibition the urease activity. Immunol J 2005, 21(5):393-396.
31. Guo G., Jia K.R., Shi Y., Liu X.F., Liu K.Y., Qi W., et al. Psychological stress enhances the colonization of the stomach by Helicobacter pylori in the BALB/c mouse. Stress 2009, 12(6):478-485.
32. Roussel Y., Wilks M., Harris A., Mein C., Tabaqchali S. Evaluation of DNA extraction methods from mouse stomachs for the quantification of H. pylori by real-time PCR. J Microbiol Methods 2005, 62(1):71-81.
33. Gomez-Duarte O.G., Lucas B., Yan Z.X., Panthel K., Haas R., Meyer T.F. Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine 1998, 16(5):460-471.
34. Koesling J., Lucas B., Develioglou L., Aebischer T., Meyer T.F. Vaccination of mice with live recombinant Salmonella typhimurium aroA against H. pylori: parameters associated with prophylactic and therapeutic vaccine efficacy. Vaccine 2001, 20(3-4):413-420.
35. Viret J.F., Favre D., Wegmuller B., Herzog C., Que J.U., Cryz SJ, et al. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect Immun 1999, 67(7):3680-3685.
36. Hopkins S., Kraehenbuhl J.P., Schodel F., Potts A., Peterson D., de Grandi P., et al. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect Immun 1995, 63(9):3279-3286.
37. Galen J.E., Gomez-Duarte O.G., Losonsky G.A., Halpern J.L., Lauderbaugh C.S., Kaintuck S., et al. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine 1997, 15(6-7):700-708.
38. Metzger W.G., Mansouri E., Kronawitter M., Diescher S., Soerensen M., Hurwitz R., et al. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2004, 22(17-18):2273-2277.
39. DiPetrillo M.D., Tibbetts T., Kleanthous H., Killeen K.P., Hohmann E.L. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 1999, 18(5-6):449-459.
40. Yelon D., Schaefer K.L., Berg L.J. Alterations in CD4-binding regions of the MHC class II molecule I-Ek do not impede CD4+ T cell development. J Immunol 1999, 162(3):1348-1358.
41. Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis 1999, 5(4):285-294.
42. Kopitar A.N., Stegel V., Tepes B., Gubina M., Novakovic S., Ihan A. Specific T cell responses to Helicobacter pylori predict successful eradication therapy. J Infect 2007, 54(3):257-261.
43. Morihara F., Hifumi E., Yamada M., Nishizono A., Uda T. Therapeutic effects of molecularly designed antigen UREB138 for mice infected with Helicobacter pylori. Biotechnol Bioeng 2008, 100(4):634-643.